The Journal of Rare Diseases and Specialty Pharmacology (JRDSP) is committed to publishing impactful, peer-reviewed research that advances clinical knowledge, pharmacological innovation, and therapeutic strategies in the management of rare and complex disorders. Our current and archived issues are fully open access, offering free and immediate access to all readers.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Targeted Enzyme Replacement Strategies for Ultra-Rare Lysosomal Storage Disorders
Vol.2(1); Pages:1-10. Published on April-2026
Abstract
Lysosomal storage disorders (LSDs) represent a heterogeneous group of ultra-rare metabolic diseases characterized by enzyme deficiencies leading to substrate accumulation. This study evaluates the efficacy and safety of next-generation targeted enzyme replacement therapy (ERT) utilizing receptor-mediated delivery systems to enhance intracellular uptake. Conducted across five international centers, the trial enrolled 84 patients diagnosed with three distinct LSD subtypes. Patients were randomized to receive either standard ERT or targeted ERT over a 24-week period. Clinical endpoints included reduction in biomarker levels, organ volume normalization, and quality-of-life improvements. Results demonstrated statistically significant improvements in targeted ERT recipients, with enhanced enzymatic activity observed at cellular levels and reduced systemic accumulation markers. Adverse events were minimal and comparable between groups. The findings support the potential of receptor-specific targeting in improving therapeutic outcomes in LSDs. Further longitudinal studies are recommended to evaluate long-term efficacy and immunogenicity.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pharmacogenomic Profiling in Orphan Drug Response Variability
Vol.2(1); Pages:11-19. Published on April-2026
Abstract
Variability in patient response to orphan drugs poses a significant challenge in rare disease management. This study investigates the role of pharmacogenomic markers in influencing therapeutic outcomes among patients receiving orphan-designated medications. A cohort of 132 patients across Europe was analyzed using whole exome sequencing to identify genetic polymorphisms associated with drug metabolism and efficacy. The study identified multiple variants in cytochrome P450 enzymes and transporter genes that significantly correlated with altered drug response profiles. Patients with specific allelic variants exhibited either subtherapeutic responses or increased adverse drug reactions. The findings emphasize the importance of integrating pharmacogenomic screening into clinical decision-making frameworks for rare diseases. Personalized therapeutic strategies guided by genetic profiling may optimize efficacy and minimize toxicity. This research highlights a paradigm shift towards precision medicine in the orphan drug landscape, necessitating further validation in larger populations.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Nanocarrier-Based Drug Delivery Systems for Rare Neurodegenerative Disorders
Vol.2(1); Pages:20-30. Published on May-2026
Abstract
Rare neurodegenerative disorders often face therapeutic limitations due to poor drug penetration across the blood-brain barrier (BBB). This study explores the development of lipid-based nanocarriers designed to enhance central nervous system drug delivery. Using in vitro BBB models and in vivo murine systems, the study evaluated drug encapsulation efficiency, permeability, and targeted release. The nanocarriers demonstrated superior BBB penetration and sustained drug release compared to conventional formulations. Behavioral and biochemical assessments in animal models showed improved neurological function and reduced neurodegeneration markers. Toxicological evaluations confirmed minimal systemic toxicity and favorable biocompatibility. These findings underscore the promise of nanocarrier-based systems in overcoming pharmacokinetic barriers in rare neurological conditions. Future clinical translation will require optimization of dosage and long-term safety profiling.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Repurposing Antiviral Agents for Rare Autoimmune Syndromes: A Systems Pharmacology Approach
Vol.2(1); Pages:31-41. Published on May-2026
Abstract
Drug repurposing offers a cost-effective strategy for addressing unmet therapeutic needs in rare autoimmune syndromes. This study employed a systems pharmacology framework to identify potential antiviral agents with immunomodulatory properties. Using network-based analyses and molecular docking simulations, candidate drugs were screened for interaction with key inflammatory pathways. Selected compounds were subsequently validated through in vitro assays using patient-derived immune cells. Results identified two antiviral agents exhibiting significant downregulation of pro-inflammatory cytokines and modulation of immune signaling pathways. These findings suggest that existing antiviral drugs may have therapeutic potential beyond their original indications. The integration of computational and experimental methodologies provides a robust platform for accelerating drug discovery in rare diseases. Further clinical investigation is warranted to establish safety and efficacy in human subjects.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Long-Term Safety Evaluation of Gene Therapy in Rare Hematological Disorders
Vol.2(1); Pages:42-52. Published on June-2026
Abstract
Gene therapy has emerged as a transformative treatment modality for rare hematological disorders such as beta-thalassemia and hemophilia. This longitudinal study assesses the long-term safety and durability of gene therapy interventions over a five-year follow-up period. Data from 56 patients who underwent viral vector mediated gene transfer were analyzed for sustained gene expression, hematological improvement, and adverse events. Results indicate stable therapeutic gene integration with persistent clinical benefits, including reduced transfusion dependency and improved clotting profiles. Notably, no cases of insertional mutagenesis or malignancy were observed. Mild immune responses were documented but managed effectively. The study provides critical evidence supporting the long-term viability of gene therapy in rare blood disorders. Continued surveillance and larger cohort studies are essential to confirm these findings and address potential late-onset complications.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
